COMPASS Pathways

CMPS Small Cap

Healthcare · Medical Care Facilities

Updated: Apr 5, 2026, 17:43 UTC

$5.79

+3.02% today

52W: $2.25 – $8.90

52W Low: $2.25 Position: 53.2% 52W High: $8.90

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

—

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$746.5M

Market Capitalization

Revenue Growth

—

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-565.28%

Return on Equity

Beta

2.02

Market sensitivity

Short Interest

5.71%

% of float sold short

Avg. Volume

2,931,204

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

12 analysts

Avg. Price Target

$21.75

+275.65% upside

Target Range

$8.00 – $70.00

About the Company

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Sector: Healthcare Industry: Medical Care Facilities Country: United Kingdom Employees: 156 Exchange: NMS